|Bid||15.21 x 2200|
|Ask||15.25 x 1000|
|Day's Range||15.09 - 15.29|
|52 Week Range||13.72 - 25.48|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||9.50|
|Earnings Date||Jan 2, 2020 - Jan 6, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.33|
The Albany region's largest medical device maker is teaming up with the area's largest advertising firm for the first time.
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 22) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...
The company has undergone a $100 million turnaround since CEO Jim Clemmer and CFO Michael Greiner joined the business a little more than three years ago.
AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer (CFO) will be departing the Company. Stephen A. Trowbridge, Senior Vice President and General Counsel, will assume the role of interim Chief Financial Officer in addition to his current responsibilities. Mr. Greiner will remain with AngioDynamics to facilitate a smooth transition of duties up to the filing of the second fiscal quarter 10-Q, and the Company has initiated a process to determine a permanent successor.
AngioDynamics CEO Jim Clemmer has spent the past two years shedding low-margin products from the Latham company's portfolio, replacing them with higher-margin emerging technology.
AngioDynamics (ANGO) delivered earnings and revenue surprises of 100.00% and -2.32%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics has acquired Israeli startup Eximo Medical Ltd. to gain a foothold in a $500 million market. The transaction gives the Latham medical device maker ownership of Eximo's laser technology, which has received approval from the U.S. Food and Drug Administration to be used for treating patients with peripheral artery disease. AngioDynamics (Nasdaq: ANGO) will pay $46 million up front.
Shares of medical device maker AngioDynamics declined significantly Thursday after the company updated its full-year earnings guidance following an acquisition. The company announced the purchase of Israeli laser company Eximo for $46 million up front, with up to another $20 million if Eximo meets technical and revenue milestones. AngioDynamics said that it now expects earnings per share for fiscal 2020 to range between 10 cents and 15 cents a share.
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in up-front consideration with up to $20 million of contingent ...
NEW YORK, NY / ACCESSWIRE / October 3, 2019 / AngioDynamics, Inc. (OTC PINK: ANGO ) will be discussing their earnings results in their 2020 First Quarter Earnings to be held on October 3, 2019 at 8:00 ...
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How far off is AngioDynamics, Inc. (NASDAQ:ANGO) from its intrinsic value? Using the most recent financial data, we'll...